Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

 Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

Shots:

  • Editas & BlueRock enter in to research collaboration to develop engineered cell therapies/ allogeneic pluripotent stem cell (PSC) lines by the combination of Editas’ CRISPR & BlueRock’s iPSC in oncology & neurology, cardiology and immunology respectively
  • According to cross-licensing agreement, BlueRock to get non-exclusive & IPR rights for Editas Medicine’s CRISPR technology and Editas to get non-exclusive & IPR rights for BlueRock’s iPSC and cell differentiation technology. The companies will also receive development, regulatory and commercial milestones & royalties on global sales of products
  • Editas’ CRISPR is a genome editing technology utilizes Cas9 or Cpf1 protein to repair broken genes. BlueRock’s iPSC is the basis of CELL+GENE platform used to replace damaged or degenerated tissue to restore or regenerate lost function

Click here to read full press release/ article | Ref: Editas Medicine | Image: PMLive

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post